Bayer (ETR:BAYN) target bumped up to 105.00EUR, released a research note earlier today by Societe Generale
- Updated: September 21, 2016
Boasting a price of 91.46EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. With the last close up -4.07% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Bayer has recorded a 50-day moving average of 0.04EUR and a 200-day moving average of 0.03EUR. 0 shares of the stock traded, down from an avg. volume of 215
Bayer (ETR:BAYN) had its price target raised to 105.00EUR by Societe Generale in an issued report announced 09/22/2016. The new stock price target indicates a possible upside of 0.15% based on the company's most recent stock price close.
Previously on 09/21/2016, Societe Generale reported on Bayer (ETR:BAYN) raised the target price from 0.00EUR to 105.00EUR. At the time, this indicated a possible upside of 0.15%.
Bayer has with a one year low of 0.03EUR and a one year high of 0.04EUR and has a market cap of 0 EUR.
About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.